KR102548547B1 - 신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린 - Google Patents

신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린 Download PDF

Info

Publication number
KR102548547B1
KR102548547B1 KR1020177013639A KR20177013639A KR102548547B1 KR 102548547 B1 KR102548547 B1 KR 102548547B1 KR 1020177013639 A KR1020177013639 A KR 1020177013639A KR 20177013639 A KR20177013639 A KR 20177013639A KR 102548547 B1 KR102548547 B1 KR 102548547B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
inhibitor
alkyl
pharmaceutical composition
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177013639A
Other languages
English (en)
Korean (ko)
Other versions
KR20170077160A (ko
Inventor
피라스 바시시
앙뚜안 베레
소니아 브륀
제롬 쿠르깡베끄
끌라리스 뒤브레
그레고리 니꼴라
필리쁘 알퐁
Original Assignee
제노사이언스 파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제노사이언스 파마 filed Critical 제노사이언스 파마
Publication of KR20170077160A publication Critical patent/KR20170077160A/ko
Application granted granted Critical
Publication of KR102548547B1 publication Critical patent/KR102548547B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177013639A 2014-10-31 2015-10-26 신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린 Active KR102548547B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
US62/073,325 2014-10-31
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (2)

Publication Number Publication Date
KR20170077160A KR20170077160A (ko) 2017-07-05
KR102548547B1 true KR102548547B1 (ko) 2023-06-27

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177013639A Active KR102548547B1 (ko) 2014-10-31 2015-10-26 신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린

Country Status (34)

Country Link
US (1) US10722505B2 (https=)
EP (1) EP3212629B1 (https=)
JP (1) JP6588546B2 (https=)
KR (1) KR102548547B1 (https=)
CN (1) CN107148416B (https=)
AU (1) AU2015338844B2 (https=)
CA (1) CA2965262C (https=)
CL (1) CL2017001073A1 (https=)
CO (1) CO2017007325A2 (https=)
CR (1) CR20170177A (https=)
CY (1) CY1121326T1 (https=)
DK (1) DK3212629T3 (https=)
DO (1) DOP2017000107A (https=)
EA (1) EA037119B1 (https=)
EC (1) ECSP17026748A (https=)
ES (1) ES2707125T3 (https=)
GE (1) GEP20207108B (https=)
HR (1) HRP20190107T1 (https=)
IL (1) IL251775B (https=)
LT (1) LT3212629T (https=)
MA (1) MA40875B1 (https=)
MY (1) MY193740A (https=)
NI (1) NI201700052A (https=)
PE (1) PE20191142A1 (https=)
PH (1) PH12017500810A1 (https=)
PL (1) PL3212629T3 (https=)
PT (1) PT3212629T (https=)
RS (1) RS58328B1 (https=)
SG (1) SG11201703479SA (https=)
SI (1) SI3212629T1 (https=)
TN (1) TN2017000168A1 (https=)
TR (1) TR201900148T4 (https=)
UA (1) UA122062C2 (https=)
WO (1) WO2016067112A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
TW202214244A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 具有協同抗癌功效之氯硝柳胺（Ｎｉｃｌｏｓａｍｉｄｅ）和雙硫侖（Ｄｉｓｕｌｆｉｒａｍ）醫藥組合物及其用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers
EP4520396A1 (en) 2023-09-05 2025-03-12 Genoscience Pharma Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US20070167459A1 (en) 2002-12-10 2007-07-19 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
RS60244B1 (sr) * 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
AU2014233757B2 (en) * 2013-03-18 2017-12-21 Genoscience Pharma Quinolines derivatives as novel anticancer agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167459A1 (en) 2002-12-10 2007-07-19 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis

Also Published As

Publication number Publication date
KR20170077160A (ko) 2017-07-05
TN2017000168A1 (en) 2018-10-19
NZ731345A (en) 2023-09-29
PT3212629T (pt) 2019-02-04
ES2707125T3 (es) 2019-04-02
CN107148416B (zh) 2020-05-05
IL251775B (en) 2020-07-30
EP3212629A1 (en) 2017-09-06
CL2017001073A1 (es) 2018-01-12
ECSP17026748A (es) 2018-03-31
IL251775A0 (en) 2017-06-29
PL3212629T3 (pl) 2019-05-31
EP3212629B1 (en) 2018-10-24
EA201790949A1 (ru) 2018-02-28
HRP20190107T1 (hr) 2019-03-08
TR201900148T4 (tr) 2019-02-21
DOP2017000107A (es) 2017-09-15
GEAP202014494A (en) 2020-01-27
MY193740A (en) 2022-10-27
MA40875B1 (fr) 2019-01-31
AU2015338844A1 (en) 2017-05-04
JP2017538673A (ja) 2017-12-28
CA2965262A1 (en) 2016-05-06
DK3212629T3 (en) 2019-02-18
GEP20207108B (en) 2020-05-11
CA2965262C (en) 2023-03-14
WO2016067112A1 (en) 2016-05-06
US10722505B2 (en) 2020-07-28
LT3212629T (lt) 2019-01-10
SG11201703479SA (en) 2017-05-30
NI201700052A (es) 2017-09-11
PE20191142A1 (es) 2019-09-02
CY1121326T1 (el) 2020-05-29
MA40875A (fr) 2017-09-06
AU2015338844B2 (en) 2019-09-19
US20190314359A1 (en) 2019-10-17
CO2017007325A2 (es) 2017-10-20
PH12017500810A1 (en) 2017-10-02
EA037119B1 (ru) 2021-02-09
RS58328B1 (sr) 2019-03-29
SI3212629T1 (sl) 2019-02-28
BR112017018637A2 (pt) 2022-07-05
JP6588546B2 (ja) 2019-10-09
CN107148416A (zh) 2017-09-08
UA122062C2 (uk) 2020-09-10
CR20170177A (es) 2017-09-19

Similar Documents

Publication Publication Date Title
KR102548547B1 (ko) 신규한 항암제로서의 치환 ２,４ 디아미노-퀴놀린
AU2014233757B2 (en) Quinolines derivatives as novel anticancer agents
KR102014326B1 (ko) 벤즈옥사제핀 옥사졸리디논 화합물 및 사용 방법
TWI609012B (zh) 氨基喹唑啉類衍生物及其鹽和使用方法
WO2020231806A1 (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
KR20240018446A (ko) 돌연변이 braf의 분해를 위한 요법
CA2851151A1 (en) Aminoquinazoline derivatives and their salts and methods of use
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
CN103319468B (zh) 取代的螺双环化合物及其使用方法和用途
CN120112514A (zh) Ulk抑制剂及其使用方法
NZ731345B2 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
HK1240587B (zh) 作为新抗癌药的被取代的2，4二氨基-喹啉
BR112017018637B1 (pt) Composto e seus usos, composição farmacêutica e seus usos e kit para tratamento e prevenção de doenças neoplásicas e não neoplásicas proliferativas
HK1240587A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
EP4673448A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
HK40100586A (en) Csf1r inhibitors for use in treating tenosynovial giant cell tumors
HK40100586B (en) Csf1r inhibitors for use in treating tenosynovial giant cell tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201023

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221005

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230504

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230623

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230623

End annual number: 3

Start annual number: 1

PG1601 Publication of registration